FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034160841> ?p ?o ?g. }

• W2034160841 endingPage "273" @default.
• W2034160841 startingPage "265" @default.
• W2034160841 abstract "BACKGROUND. Therapy for patients with myelodysplastic syndrome (MDS) with hypomethylating agents, like decitabine and 5-azacitidine, has produced favorable results. In this study, the authors update their experience with decitabine in patients with MDS and analyze the cytogenetic response patterns and prognostic factors associated with decitabine therapy. METHODS. One hundred fifteen patients with higher risk MDS who received treatment with decitabine were reviewed. Patients received decitabine 100 mg/m2 per course every 4 weeks in 3 different schedules: 1) 20 mg/m2 intravenously daily × 5, 2) 20 mg/m2 subcutaneously daily × 5, and 3) 10 mg/m2 intravenously daily × 10. Decitabine was given for a median of ≥7 courses (range, 1–23 courses). RESULTS. Overall, 80 patients (70%) achieved a response according to the modified International Working Group criteria (IWG): complete response (CR), 40 patients (35%); partial response, 2 patients (2%); bone marrow CR with or without other hematologic improvements (HI), 26 patients (23%); and other HI, 12 patients (10%). Cytopenias were improved in 50% of patients. The median remission duration was 20 months, and the median survival was 22 months. Mortality was 3% at 6 weeks and 7% at 3 months. In a multivariate analysis, poor prognostic factors for achieving IWG CR were MDS (vs chronic myelomonocytic leukemia), longer duration of MDS, and prior MDS therapy. For survival, independent adverse prognostic factors were chromosome 5 and/or 7 abnormalities, older age, and prior MDS therapy (excluding growth factors). CONCLUSIONS. The longer term experience with decitabine in MDS was favorable. Pretreatment prognostic factors may predict the outcome of patients who receive decitabine therapy for MDS. Cancer 2007. © 2006 American Cancer Society." @default.
• W2034160841 created "2016-06-24" @default.
• W2034160841 creator A5000750846 @default.
• W2034160841 creator A5006104041 @default.
• W2034160841 creator A5012594007 @default.
• W2034160841 creator A5015101485 @default.
• W2034160841 creator A5020254333 @default.
• W2034160841 creator A5038541414 @default.
• W2034160841 creator A5042509365 @default.
• W2034160841 creator A5049385583 @default.
• W2034160841 creator A5059555096 @default.
• W2034160841 creator A5090435894 @default.
• W2034160841 date "2007-01-01" @default.
• W2034160841 modified "2023-10-18" @default.
• W2034160841 title "Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome" @default.
• W2034160841 cites W187238933 @default.
• W2034160841 cites W2002226188 @default.
• W2034160841 cites W2004614297 @default.
• W2034160841 cites W2077183730 @default.
• W2034160841 cites W2081279521 @default.
• W2034160841 cites W2094615848 @default.
• W2034160841 cites W2106584820 @default.
• W2034160841 cites W2117291755 @default.
• W2034160841 cites W2129510594 @default.
• W2034160841 cites W2131639268 @default.
• W2034160841 cites W2159104864 @default.
• W2034160841 cites W2159507916 @default.
• W2034160841 cites W2268739714 @default.
• W2034160841 cites W4240525086 @default.
• W2034160841 cites W4253916874 @default.
• W2034160841 cites W4376595466 @default.
• W2034160841 doi "https://doi.org/10.1002/cncr.22376" @default.
• W2034160841 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17133405" @default.
• W2034160841 hasPublicationYear "2007" @default.
• W2034160841 type Work @default.
• W2034160841 sameAs 2034160841 @default.
• W2034160841 citedByCount "103" @default.
• W2034160841 countsByYear W20341608412012 @default.
• W2034160841 countsByYear W20341608412013 @default.
• W2034160841 countsByYear W20341608412014 @default.
• W2034160841 countsByYear W20341608412015 @default.
• W2034160841 countsByYear W20341608412016 @default.
• W2034160841 countsByYear W20341608412017 @default.
• W2034160841 countsByYear W20341608412018 @default.
• W2034160841 countsByYear W20341608412019 @default.
• W2034160841 countsByYear W20341608412020 @default.
• W2034160841 countsByYear W20341608412021 @default.
• W2034160841 countsByYear W20341608412022 @default.
• W2034160841 countsByYear W20341608412023 @default.
• W2034160841 crossrefType "journal-article" @default.
• W2034160841 hasAuthorship W2034160841A5000750846 @default.
• W2034160841 hasAuthorship W2034160841A5006104041 @default.
• W2034160841 hasAuthorship W2034160841A5012594007 @default.
• W2034160841 hasAuthorship W2034160841A5015101485 @default.
• W2034160841 hasAuthorship W2034160841A5020254333 @default.
• W2034160841 hasAuthorship W2034160841A5038541414 @default.
• W2034160841 hasAuthorship W2034160841A5042509365 @default.
• W2034160841 hasAuthorship W2034160841A5049385583 @default.
• W2034160841 hasAuthorship W2034160841A5059555096 @default.
• W2034160841 hasAuthorship W2034160841A5090435894 @default.
• W2034160841 hasBestOaLocation W20341608411 @default.
• W2034160841 hasConcept C104317684 @default.
• W2034160841 hasConcept C126322002 @default.
• W2034160841 hasConcept C143998085 @default.
• W2034160841 hasConcept C150194340 @default.
• W2034160841 hasConcept C185592680 @default.
• W2034160841 hasConcept C190727270 @default.
• W2034160841 hasConcept C2776012956 @default.
• W2034160841 hasConcept C2776239401 @default.
• W2034160841 hasConcept C2777928532 @default.
• W2034160841 hasConcept C2780007613 @default.
• W2034160841 hasConcept C2780235182 @default.
• W2034160841 hasConcept C2780240888 @default.
• W2034160841 hasConcept C2780817109 @default.
• W2034160841 hasConcept C38180746 @default.
• W2034160841 hasConcept C50382708 @default.
• W2034160841 hasConcept C55493867 @default.
• W2034160841 hasConcept C71924100 @default.
• W2034160841 hasConceptScore W2034160841C104317684 @default.
• W2034160841 hasConceptScore W2034160841C126322002 @default.
• W2034160841 hasConceptScore W2034160841C143998085 @default.
• W2034160841 hasConceptScore W2034160841C150194340 @default.
• W2034160841 hasConceptScore W2034160841C185592680 @default.
• W2034160841 hasConceptScore W2034160841C190727270 @default.
• W2034160841 hasConceptScore W2034160841C2776012956 @default.
• W2034160841 hasConceptScore W2034160841C2776239401 @default.
• W2034160841 hasConceptScore W2034160841C2777928532 @default.
• W2034160841 hasConceptScore W2034160841C2780007613 @default.
• W2034160841 hasConceptScore W2034160841C2780235182 @default.
• W2034160841 hasConceptScore W2034160841C2780240888 @default.
• W2034160841 hasConceptScore W2034160841C2780817109 @default.
• W2034160841 hasConceptScore W2034160841C38180746 @default.
• W2034160841 hasConceptScore W2034160841C50382708 @default.
• W2034160841 hasConceptScore W2034160841C55493867 @default.
• W2034160841 hasConceptScore W2034160841C71924100 @default.
• W2034160841 hasIssue "2" @default.
• W2034160841 hasLocation W20341608411 @default.
• W2034160841 hasLocation W20341608412 @default.

• next